Contineum Therapeutics (CTNM) Total Current Liabilities (2023 - 2026)

Contineum Therapeutics' Total Current Liabilities history runs 4 years deep, the most recent figure standing at $6.7 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 25.61% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $6.7 million (down 25.61% YoY), while the FY2025 annual figure was $9.7 million, down 2.31% from the prior year.
• Total Current Liabilities was $6.7 million for Q1 2026 at Contineum Therapeutics, down from $9.7 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $10.0 million in Q4 2024 to a low of $3.7 million in Q2 2024.
• Historically, Total Current Liabilities has averaged $7.0 million across 4 years, with a median of $6.5 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Total Current Liabilities soared 92.94% in 2025, then declined 25.61% in 2026.
• A 4-year view of Total Current Liabilities shows it stood at $5.5 million in 2023, then soared by 81.87% to $10.0 million in 2024, then fell by 2.31% to $9.7 million in 2025, then slumped by 31.68% to $6.7 million in 2026.
• The last three Total Current Liabilities figures came in at $6.7 million (Q1 2026), $9.7 million (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.